Wall Street analysts predict that Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) will report ($0.19) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Nabriva Therapeutics’ earnings, with estimates ranging from ($0.20) to ($0.18). Nabriva Therapeutics reported earnings per share of ($0.53) in the same quarter last year, which would indicate a positive year-over-year growth rate of 64.2%. The company is expected to report its next quarterly earnings results after the market closes on Monday, January 1st.
According to Zacks, analysts expect that Nabriva Therapeutics will report full year earnings of ($0.67) per share for the current fiscal year, with EPS estimates ranging from ($0.73) to ($0.61). For the next financial year, analysts anticipate that the firm will post earnings of ($0.34) per share, with EPS estimates ranging from ($0.35) to ($0.33). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Nabriva Therapeutics.
Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) last announced its quarterly earnings results on Tuesday, March 29th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.05). The company had revenue of $9.26 million for the quarter, compared to analyst estimates of $10.30 million. Nabriva Therapeutics had a negative return on equity of 82.13% and a negative net margin of 171.14%. During the same quarter last year, the company posted ($1.11) earnings per share.
Shares of NASDAQ:NBRV opened at $0.31 on Monday. The company has a fifty day moving average of $0.40 and a 200-day moving average of $0.62. The company has a market capitalization of $184.66 million, a PE ratio of -0.24 and a beta of 1.57. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.94 and a current ratio of 3.59. Nabriva Therapeutics has a 52-week low of $0.28 and a 52-week high of $2.32.
Institutional investors have recently modified their holdings of the stock. Advisor Group Holdings Inc. grew its stake in shares of Nabriva Therapeutics by 5,200.0% in the third quarter. Advisor Group Holdings Inc. now owns 26,500 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 26,000 shares during the last quarter. Renaissance Technologies LLC boosted its position in Nabriva Therapeutics by 116.3% during the fourth quarter. Renaissance Technologies LLC now owns 471,300 shares of the biotechnology company’s stock valued at $282,000 after acquiring an additional 253,415 shares during the last quarter. Virtu Financial LLC bought a new stake in Nabriva Therapeutics during the fourth quarter valued at $125,000. Morgan Stanley boosted its position in Nabriva Therapeutics by 832.2% during the second quarter. Morgan Stanley now owns 91,939 shares of the biotechnology company’s stock valued at $125,000 after acquiring an additional 82,076 shares during the last quarter. Finally, Millennium Management LLC boosted its position in Nabriva Therapeutics by 218.5% during the third quarter. Millennium Management LLC now owns 99,151 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 68,018 shares during the last quarter. 1.55% of the stock is currently owned by institutional investors.
About Nabriva Therapeutics (Get Rating)
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- World Wresting Entertainment Stock is Hulking Up
- High-Yield Weyco Group Returns To Reasonable Levels
- MarketBeat Podcast: Alternative Investing Strategies Despite Market Volatility
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.